We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Group enriched (glioma, prostate cancer, testis cancer)
HPA (cell line):
Group enriched (AF22, HEK93, NTERA-2, SH-SY5Y, U-2 OS)
HPA (normal tissue):
Tissue enhanced (testis)
Protein evidence
Evidence at protein level
Protein expression normal tissue
Cytoplasmic expression in several tissue types.
ANTIBODY IHC RELIABILITY
Data reliability description
Antibody staining mainly not consistent with RNA expression data. Pending external verification. Caution, targets protein from more than one gene. Presumed off target binding observed and disregarded.
Most cases of prostate cancers along with fractions of cases in other cancers displayed moderate to strong cytoplasmic and/or membranous staining as well as extracellular positivity. Remaining cancers were generally negative.
This gene is a member of the nudix (nucleoside diphosphate linked moiety X)-type motif containing family. The encoded protein is a phosphohydrolase and may regulate the turnover of diphosphoinositol polyphosphates. The turnover of these high-energy diphosphoinositol polyphosphates represents a molecular switching activity with important regulatory consequences. Molecular switching by diphosphoinositol polyphosphates may contribute to the regulation of intracellular trafficking. In some populations putative prostate cancer susceptibility alleles have been identified for this gene. Alternatively spliced transcript variants, which differ only in the 5' UTR, have been found for this gene. [provided by RefSeq, Feb 2015]